In this video clip from OncLive, Director of the CLL Research Center, Richard R. Furman, M.D. discusses the new treatments that have changed the care for patients with chronic lymphocytic leukemia (CLL).
Tag: CLL
ASCO 2015: Safety of Idelalisib in B-cell Malignancies: Integrated Analysis of Eight Clinical Trials
Idelalisib is a first in class, selective, oral inhibitor of PI3Kδ approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL) in combination with rituximab and as a monotherapy for patients with follicular lymphoma, who have received at least two prior systemic therapies. A recent study sought to analyze the safety profile of idelalisib in 760 subjects with heavily pre-treated and relapsed CLL, non-Hodgkin lymphoma, and other B-cell malignancies, who received idelalisib alone or as part of a combination therapy. Side effects leading to changes in dosing included transaminase elevations (13%), diarrhea/colitis (11%), and rash. Side effects leading to discontinuation of treatment were rare. Patient’s whose dose was interrupted due to adverse events were frequently able to tolerate dosing upon re-challenge. These data demonstrate that idelalisib was well tolerated in patients as a monotherapy or in combination.
Ask the Doctor: Updates on Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma
The Lymphoma Research Foundation’s (LRF) “Ask the Doctor About Lymphoma” programs are designed specifically for people affected by lymphoma. Tonight’s two-hour topic-specific seminar will feature a presentation led by Director of the CLL Research Center, Dr. Richard Furman. The presentation will be followed by a Q&A session. Online registration is available here. Program details are below:
Ask the Doctor: Updates on Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma
Richard R. Furman, MD
Associate Professor of Medicine
Director of the CLL Research Center
Weill Cornell Medical College
New York, NY
Follow Dr. Furman on Twitter
Date and Time
Tuesday, May 12, 2015
Networking: 6:00 PM
Program: 6:30 PM – 8:30 PM
Location
New York Marriott East Side
525 Lexington Ave at 49th Street
New York, NY 10017
www.marriott.com
Meals
Dinner will be provided for all registered attendees.
Program Overview – Online registration here
-
Overview and Treatment Options on CLL/SLL
-
Understanding Clinical Trials and Novel Therapies for CLL/SLL
-
Question and Answer Session
Registration Instructions
This program is offered free-of-charge to members of the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma community however, pre-registration is required. Please note: The names and phone numbers and/or email address for all attendees is required to complete the registration.
Three Easy Ways to Register!
Call: 800-500-9976
Email: mspellman@lymphoma.org
Web: Click here
New Developments in Lymphoma 